Lentivirus-mediated gene therapy for Fabry disease

Area of Science:

• Biochemistry
• Genetics
• Hematology

Background:

• Fabry disease is a genetic disorder requiring enzyme replacement therapy.
• Current enzyme and chaperone therapies for Fabry disease are costly and have limited efficacy.
• Novel therapeutic strategies are needed for Fabry disease management.

Purpose of the Study:

• To evaluate the safety and efficacy of autologous lentivirus-transduced hematopoietic stem/progenitor cell therapy in adult males with Fabry disease.
• To assess the production of alpha-galactosidase A (α-gal A) and reduction of Gb3 and lyso-Gb3 levels post-treatment.
• To determine the long-term feasibility of this gene therapy approach.

Main Methods:

• A pilot, single-arm study involving five adult males with Type 1 Fabry disease.
• Infusion of autologous CD34+-selected hematopoietic stem/progenitor cells engineered to express α-gal A.
• Non-myeloablative preparative regimen with intravenous melphalan.

Main Results:

• No serious adverse events were attributed to the investigational product.
• All patients achieved near-normal α-gal A levels within one week post-infusion.
• Reductions in plasma and urine Gb3 and lyso-Gb3 were observed, with sustained α-gal A activity.

Conclusions:

• Autologous lentivirus-transduced stem cell therapy is a safe and potentially effective treatment for Fabry disease.
• This gene therapy approach leads to sustained enzyme production and substrate reduction.
• The findings suggest a promising alternative to conventional enzyme replacement therapy for Fabry disease.